The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment

Arthritis and Rheumatism

Volumn 64, Issue 10, 2012, Pages 3119-3128

  Gordon, Rachael A ^a   Grigoriev, Galina ^a   Lee, Angela ^a   Kalliolias, George D ^a   Ivashkiv, Lionel B ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GELATINASE B; INTERLEUKIN 8; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MACROPHAGE; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYNOVIAL FLUID;

ADULT; ARTHRITIS, RHEUMATOID; HUMANS; INTERFERON TYPE I; INTERLEUKIN-8; MACROPHAGES; MATRIX METALLOPROTEINASE 9; SPONDYLARTHRITIS; STAT1 TRANSCRIPTION FACTOR; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869017379     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34544     Document Type: Article

References (49)

1. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347-53. (Pubitemid 20146364)
2. Van Der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003; 48: 2132-45. (Pubitemid 36959193)
3. Antoniv TT, Ivashkiv LB. Dysregulation of interleukin- 10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum 2006; 54: 2711-21. (Pubitemid 44497750)
4. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-21. (Pubitemid 24217131)
5. Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, Van Der Pouw Kraan TC, et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004;63: 233-9. (Pubitemid 38250663)
6. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, et al. Sensitization of IFN-Jak-STAT signaling during macrophage activation. Nat Immunol 2002; 3: 859-66.
7. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006; 65: 1558-64. (Pubitemid 44799665)
8. Kalliolias GD, Ivashkiv LB. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J Immunol 2008; 180: 6325-33.
9. Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev 2008; 226: 41-56.
10. Ji JD, Tassiulas I, Park-Min KH, Aydin A, Mecklenbrauker I, Tarakhovsky A, et al. Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis. J Exp Med 2003; 197: 1573-83. (Pubitemid 36682553)
11. Sengupta TK, Chen A, Zhong Z, Darnell JE Jr, Ivashkiv LB. Activation of monocyte effector genes and STAT family transcription factors by inflammatory synovial fluid is independent of interferon -. J Exp Med 1995; 181: 1015-25.
12. Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum 2010; 62: 402-13.
13. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67: 227-64. (Pubitemid 28411130)
14. Van Der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007; 66: 1008-14. (Pubitemid 47122311)
15. Van Holten J, Smeets TJ, Blankert P, Tak PP. Expression of interferon - in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005; 64: 1780-2. (Pubitemid 41667156)
16. Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferonresponse genes. Nat Immunol 2008; 9: 378-87. (Pubitemid 351405107)
17. Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-/-ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum 2010; 62: 392-401.
18. Van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, Van Der Pouw Kraan TC, Baeten DL, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010;12:R11.
19. Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010; 62: 3607-14.
20. Vosslamber S, Raterman HG, Van Der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1153-9.
21. Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther 2010;12 Suppl 1:S1.
22. Buttmann M, Rieckmann P. Interferon-beta1b in multiple sclerosis. Expert Rev Neurother 2007; 7: 227-39.
23. Yarilina A, DiCarlo E, Ivashkiv LB. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol 2007; 178: 2204-11. (Pubitemid 46233418)
24. Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol 2009; 3:559-66.
25. Kotter I, Hamuryudan V, Ozturk ZE, Yazici H. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 2010; 22: 278-83.
26. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-, interleukin-12, and tumor necrosis factor - production by interferon-gene therapy. Arthritis Rheum 1999; 42: 90-9.
27. Van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater- Zyberk C, Vervoordeldonk MJ, et al. Treatment with recombinant interferon-reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004;6:R239-49.
28. Corr M, Boyle DL, Ronacher L, Flores N, Firestein GS. Synergistic benefit in inflammatory arthritis by targeting I-B kinase - and interferon -. Ann Rheum Dis 2009; 68: 257-63.
29. Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005; 115: 695-702. (Pubitemid 40322244)
30. Genovese MC, Chakravarty EF, Krishnan E, Moreland LW. A randomized, controlled trial of interferon-beta-1a (Avonex®) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis Res Ther 2004;6:R73-7.
31. Van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, et al. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 64-9. (Pubitemid 40075277)
32. Feldmann M. Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 2009; 27: 1-27.
33. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF - antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244-7. (Pubitemid 19180612)
34. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colonystimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-. Eur J Immunol 1991; 21: 2575-9.
35. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31. (Pubitemid 21905432)
36. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510-4. (Pubitemid 23000469)
37. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor - and transforming growth factor - during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 1992; 89: 7375-9.
38. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784-8.
39. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370: 1861-74. (Pubitemid 350180008)
40. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
41. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, et al. Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell 2005; 122: 707-21. (Pubitemid 41242636)
42. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989;2 Suppl:177-86.
43. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, et al. Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med 2006; 203: 1891-901. (Pubitemid 44188464)
44. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjögren's syndrome. J Autoimmun 2010;35: 225-31.
45. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003; 36: 481-90. (Pubitemid 37498244)
46. Ronnblom L, Eloranta ML, Alm GV. Role of natural interferon-producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 2003; 36: 463-72. (Pubitemid 37498242)
47. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-in autoimmune diseases. Proc Natl Acad Sci U S A 2005; 102: 3372-7. (Pubitemid 40328052)
48. Kalliolias GD, Gordon RA, Ivashkiv LB. Suppression of TNF-and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J Immunol 2010; 185: 7047-56.
49. Ahmed ST, Ivashkiv LB. Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol 2000; 165: 5227-37.